How do RNA-, protein- or stem cell-based therapies work? How can data science methods from bioinformatics and artificial intelligence be used to develop new pharmaceutical active substances? Students at Ulm University are learning this in the new master’s programme in Pharmaceutical and Molecular Biotechnology (PMB).

How can the human body be stimulated to build more bone, thus helping those affected by osteoporosis? Researchers in Ulm have investigated the role played by the protein molecule Axl in this process. Their efforts were successful: in a study, they demonstrated that Axl inhibits bone formation – and that cells produce significantly more bone tissue when the molecule is blocked using medication. There are no discernible harmful side effects.

A revolution in glass processing technology for the medical technology sector - 07/10/2026

The Freiburg-based start-up Glassomer is rethinking materials

Glassomer has developed an innovative process for producing pure quartz glass. The result is geometrically complex glass components with micrometre-level precision that can be reproduced consistently at a fraction of the energy cost of conventional glass-melting processes. The company focuses in particular on customised products for diagnostic, therapeutic and microfluidic applications.

The start-up xenko has been awarded an EXIST grant of 143,500 € from the Federal Ministry for Economic Affairs and Energy. The team of founders from Ulm University is developing a digital health platform designed to encourage more physical activity in everyday working life through virtual reality. This development is of interest to companies with occupational health management schemes and, in the long term, to the physiotherapy sector as well.

How can cell-based immunotherapies for cancer and autoimmune diseases become more widely available in the long term? The SYNTHIA project is addressing this challenge: The Max Planck Institute for Medical Research and the Fraunhofer Institute for Cell Therapy and Immunology IZI are collaborating on new research approaches to advance the development of cell-based immunotherapies.

Thanks to enzyme-based biocatalysis, an enormous range of pharmaceutical active ingredients and other complex molecules can be synthesized in an environmentally friendly manner. Researchers at the Karlsruhe Institute of Technology (KIT) have now developed a technology that allows to assemble enzymes into millimeter-sized, storable beads. In this process, the enzymes not only act as catalysts but also constitute the beads’ material itself.

CAR T-cell therapies are used successfully to treat certain blood cancers. However, while some patients respond even to low-dose treatment, others derive no benefit. Researchers from the Heidelberg Faculty of Medicine at Heidelberg University and the Berlin Institute of Health at Charité (BIH) investigated the reasons behind these differences in a collaborative research project.

Coughing, phlegm, and shortness of breath can be early signs of COPC. In COPD, the airways are permanently narrowed, making it harder to breathe. The most significant risk factor is long-term smoking. The CHRONOS study conducted by the Department of Pneumology at the Medical Center – University of Freiburg provides evidence that changes in the lungs can already be detected before a standard pulmonary function test confirms the airway narrowing.

How can a respiratory virus be stopped before it spreads throughout the body? In the MucoShield project, Prime Vector Technologies, the NMI Tübingen, and Fraunhofer IGB are developing an intranasal vaccine candidate against human metapneumovirus (HMPV), which causes hundreds of thousands of cases of severe respiratory disease worldwide each year – especially among children, older people, and immunocompromised individuals.

The NanoLYRIC project: nanoparticles as drug carriers - 13/08/2026

Radiation-activated local chemotherapy

Conventional chemotherapy is associated with severe side effects because cytotoxic drugs act on the whole body. Researchers at the Karlsruhe Institute of Technology and the University Medical Centre Göttingen, in collaboration with Aalen University of Applied Sciences, are developing a novel approach in which a chemotherapeutic agent encapsulated in nanoparticles is released locally and selectively only upon targeted irradiation of the tumour.

Researchers are developing biotechnological processes that enable microbes to produce proteins and vitamins for human consumption using basic chemical ingredients, such as carbon dioxide, hydrogen and oxygen – entirely bypassing livestock farming and agriculture. Because these methods also require energy input, they are popularly called “power-to-protein” and “power-to-vitamin” processes.

Researchers from the Medical Faculty Heidelberg, the Medical Faculty Mannheim, and the Centre for Organismal Studies at Heidelberg University have launched a new research project investigating so-called dipeptides. The consortium aims to determine which dipeptides have the strongest protective effects and how they could be harnessed in future therapies for vascular and kidney diseases.

The international research project MitoContact is dedicated to investigating how organelles within a cell communicate and interact with other cellular components. Kai Johnsson, Director at the Max Planck Institute for Medical Research, has received funding from the ERC for this project. The findings are expected to provide new insights into fundamental cellular processes and contribute to a better understanding of various diseases.

Robots that can learn and adapt require not only data, AI tools, and algorithms but also direct communication with their users. Jens Kober would like to improve this interaction and as the new head of a research team at Fraunhofer IPA, he is focusing in particular on construction robotics.

Prime Vector Technologies GmbH (PVT), a clinical-stage biotechnology company focusing on the development of viral vector-based vaccines, today announced that it has entered into an agreement with Boehringer Ingelheim for the assignment of certain patents and the exclusive licensing of its Orf virus (ORFV) platform for the development of next-generation cancer vaccines.

Researchers at the German Cancer Research Center (DKFZ) have identified a previously unknown key mechanism by which cancer cells suppress the immune system and thus evade the effects of immunotherapies. At the same time, the new study in mouse models and human tumor samples points to a promising way to prevent resistance to immunotherapy.

Certain medicines contain compounds known as PFAS, which are causing increasing environmental harm due to their long-lasting effects. A report by the University of Freiburg, commissioned by the German Environment Agency, shows that many PFAS-based active ingredients used in medicines can be replaced by alternatives. Based on the findings of the report, doctors will in future be able to give preference to prescribing PFAS-free medicines.

Gelatin is a versatile natural material. To tailor its properties specifically to the various applications in medicine, diagnostics, and cosmetics, the Fraunhofer IGB has developed a toolbox for chemical functionalization. With the help of automated processes, the modifications can now be scaled under defined conditions, and reproducible batches of modified gelatin can be produced on a scale ranging from grams to kg for customer sampling.

It goes without saying that new drug compounds should place as little strain on the heart as possible. But how can potential effects be reliably predicted? Researchers from the NMI, Hannover Medical School (project lead), the Universitat Politecnica de Valencia, and industry partners Multi Channel Systems and Foresee Biosystems are tackling this challenge in the new HEARTCORE project.

NEURA Robotics (“NEURA”), the pioneer in cognitive robotics and creator of the Neuraverse, today announced a landmark Series C financing with a total round size of up to $1.4 billion to accelerate its mission of building the world’s leading Physical AI platform. The financing brings together global leaders across AI, robotics, compute, manufacturing and industrial infrastructure.

Researchers at Heidelberg Faculty of Medicine at Heidelberg University, in collaboration with partners from 29 German study centers, have found evidence of a potential biomarker for personalized therapy of acute myeloid leukemia (AML) in a Phase II study. Analyses showed that certain patients could benefit from additional treatment with the drug Motixafortide in addition to standard chemotherapy.

In response to stress or damage, cells undergo senescence and stop dividing. However, if senescent cells accumulate in tissues over the long term, chronic inflammation occurs and the risk of cancer increases. Researchers at the German Cancer Research Center (DKFZ) have now discovered a previously unknown mechanism by which senescent cells protect themselves from oxidative stress and a specific form of cell death known as ferroptosis.

How can effective treatments for neuropsychiatric disorders be developed without having to accept unwanted side effects? Researchers at the NMI have made an important contribution to this field. In their recent paper, “NMDA receptor subtype differential affinity as a key enabler for precision neuropsychiatry,” they demonstrate how specifically targeting subunits of the NMDA receptor opens up new avenues for safer medications.

How do antimetabolite cancer drugs damage the genetic material of malignantly transformed cells and thereby destroy them? How might these drugs be used more precisely, particularly in the treatment of pediatric tumors? A new research group led by Dr. Christopher Carnie, a scientist at the Heidelberg Faculty of Medicine at Heidelberg University, will address these questions.